No Detail Found!

Initial results of efficacy and safety of Sofosbuvir among Pakistani Population: A real life trial Hepatitis Eradication Accuracy Trial of Sofosbuvir (HEATS)

Author(s)
Zahid Azam Dow University of Health Sciences,Karachi, Pakistan
Muhammad Shoaib Memom Medical Institute Hospital, Karachi, Pakistan
Masood Javed Punjab Medical Collage Faisalabad, Pakistan.
Muhammad Adnan Sarwar FCPS(Medicine),Senior Registrar DHQ Hospital Faisalabad, Pakistan
Hafeezullah Shaikh National Institute of liver & GI Diseases (NILGID),Dow University Hospital, Karachi, Pakistan
Nasir Khokhar Shifa International Hospital and Shifa Tameer e Millat University,Islamabad, Pakistan.
Abstract
Objective: The uridine nucleotide analogue sofosbuvir is a selective inhibitor of hepatitis C virus (HCV) NS5B polymerase approved for the treatment of chronic HCV infection with genotypes 1 - 4. The objective of the study was to evaluate the interim results of efficacy and safety of regimens containing Sofosbuvir (Zoval) among Pakistani population with the rapid virologic response (RVR2/4 weeks) with HCV infections. Methods: This is a multicenter open label prospective observational study. Patients suffering from chronic Hepatitis C infection received Sofosbuvir (Zoval) 400 mg plus ribavirin (with or without peg interferon) for 12/24 weeks. The interim results of this study were rapid virological response on week 4. Data was analyzed using SPSS version 21 for descriptive statistics. Results: A total of 573 patients with HCV infection were included in the study. The mean age of patients was 46.07 ± 11.41 years. Out of 573 patients 535 (93.3%) were treatment naive, 26 (4.5%) were relapser, 7 (1.2%) were non-responders and 5 (1.0%) were partial responders. A rapid virologic response was reported in 563(98.2%) of patients with HCV infection after four weeks of treatment. The treatment was generally well tolerated. Conclusion: Sofosbuvir (Zoval) is effective and well tolerated in combination with ribavirin in HCV infected patients.
Publication Details
Page(s) 48-52
DOI DOI not available
Published Journal: Pakistan Journal of Medical Sciences, Volume: 33, Issue: 1, Year: 2017

Request the full text from PASTIC

Keywords
Sofosbuvir, HCV infection, Rapid virologic response (RVR)
0

Citations

0

Downloads

83

Views